The 2025 Berger and Green Heart Disease Scholarship Announced
Pittsburgh, PA – The law firm of Berger and Green, dedicated to supporting injured and disabled individuals across Pennsylvania for over 40 years, reminds students that the deadline to apply for the 2025 Berger and Green Heart Disease Scholarship is June 15. Since 2017, the firm has awarded an annual scholarship of $1,000.00 to a deserving student living with heart disease, and this year is no exception.
Heart disease remains the leading cause of death in the United States, and the number of young people diagnosed with the condition continues to rise. Recognizing the challenges heart disease presents, the Berger and Green team created this scholarship to help students continue their education and achieve their goals despite their diagnosis.
'We believe that heart disease should not stand in the way of a student's ability to pursue their dreams,' said managing partner Amanda Bonnesen of Berger and Green. 'Everyone deserves the opportunity to succeed, and we are proud to support students who are overcoming the difficulties posed by heart disease.'
In past years, the firm awarded deserving individuals from Drexel University, West Virginia University, Dickinson State University, and Duquesne University.
Eligibility Requirements:
The Berger and Green Heart Disease Scholarship is available to both undergraduate and graduate students in the U.S. who are living with heart disease or a congenital heart defect. To apply, students must meet the following eligibility criteria:
• Be diagnosed with heart disease or a congenital heart defect.
• Be enrolled in or accepted to an accredited U.S. college or university.
• Maintain a minimum GPA of 3.0.
• Submit an application form, along with a copy of your transcript and a 500- to 1,000-word essay. (More details on the essay below.)
• Agree to the terms and conditions outlined for the scholarship.
How to Apply:
Students interested in applying for the Berger and Green Heart Disease Scholarship can complete the application form on the Berger and Green website. Along with the application, applicants must include their transcripts and essay.
The deadline for the 2025 scholarship is June 15th, 2025.
For more details on the application process, essay requirements, and terms and conditions, visit the Berger and Green website.
About Berger and Green:
For over 40 years, Berger and Green has been providing legal representation to individuals facing personal injuries and disabilities. The firm is committed to giving back to the community and supporting those who need it most, including students living with heart disease.
The team encourages all eligible students to apply and looks forward to helping the scholarship recipient continue their education and achieve their goals. To learn more about the previous winners, visit the firm's website here.
Anyone interested to learn more about Berger and Green's community involvement should contact Nicole Meta at 412-661-1400.
Media Contact:
Company: Berger and Green
Contact Person: Nicole Meta
Email: [email protected]
Website: https://www.bergerandgreen.com/
Disclaimer: This content does not constitute an offer to sell, a solicitation to buy, or a recommendation of any security, product, or service. Furthermore, nothing in this press release should be interpreted as a suggestion to buy, sell, or hold any investment or security, or to participate in any specific investment strategy or transaction. It is your responsibility to assess the suitability of any investment, investment strategy, security, or related transaction based on your individual objectives, financial circumstances, and risk tolerance. Please consult your financial advisor, attorney, or tax advisor for guidance on your specific financial, legal, or tax situation. For more information, contact [email protected].
Source published by Submit Press Release >> The 2025 Berger and Green Heart Disease Scholarship Announced
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
06-08-2025
- Yahoo
New Data Analyses from Groundbreaking Pivotal Bridge to HOPE Clinical Trial Demonstrate Statistically Significant Clinical, Economic and Immunomodulatory Advantages in Liver Transplantation
Presentations showcased at World Transplant Congress in San Francisco demonstrate HOPE reduces the cost of liver transplantation by shortening the index hospitalization and decreasing late complications HOPE was associated with significantly less severe organ rejection and a significantly lower risk of steroid resistant organ rejection CHICAGO, Aug. 6, 2025 /PRNewswire/ -- Following the unveiling of 12-month follow-up results from the pivotal Bridge to HOPE trial during the World Transplant Congress (WTC) 2025 Plenary Session, additional analyses of the data demonstrate that Hypothermic Oxygenated Perfusion (HOPE), in conjunction with the VitaSmartTM Perfusion System, can provide significant cost-savings for hospital systems without compromising quality of care, and reduce the severity of organ rejection, including steroid resistant rejection. The results of these analyses were presented in oral abstract sessions by David Axelrod, MD, University Hospitals Cleveland Medical Center, OH ("Economic Assessment of Hypothermic Oxygenated Machine Perfusion in Liver Transplantation") and David J. Reich, MD, FACS, Drexel University, Philadelphia, PA ("Decreased Rejection Severity with Hypothermic Oxygenated Perfusion: Sub Analysis from a Pivotal Multicenter Trial of HOPE for Liver Transplantation"). The data were part of the 12-month follow-up study of the Bridge to Life Ltd. Bridge to Hope clinical trial (HOPE with VitaSmartTM Machine Perfusion System). "Building on the 12‑month follow‑up Bridge to HOPE clinical trial data presented in the Plenary Session, these additional analyses further strengthen the evidence for the value that HOPE used with the VitaSmart™ Perfusion System brings to the transplant community," said Don Webber, CEO and President of Bridge to Life Ltd., sponsor of the Bridge to HOPE clinical trial. "Bridge to Life is committed to partnering with Transplant Centers, Organ Procurement Organizations, and Hospitals to lower total cost of care while delivering the highest‑quality patient outcomes—by shortening hospital stays and reducing post‑transplant complications, including the risk of severe and steroid‑resistant rejection. Our broad presence at WTC 2025 underscores our leadership in advancing transplant science." In the economic analysis, compared with standard static cold storage (SCS), liver transplantation using HOPE reduced initial post-liver transplantation hospital length of stay (10.8 vs. 12.9 days), costs associated with biliary complications (20.2% vs. 24.6%), re-transplants (1.8% vs. 4.5%), and death (2.8% vs. 3.6%). Further, HOPE reduced one-year post-transplant costs by an average of $28,565, according to Centers for Medicare & Medicaid Services (CMS) data. Researchers concluded that HOPE for a minimum 1.5 hours at the recipient hospital reduced the cost of liver transplantation by shortening the index hospitalization and decreasing late complications. Additional financial benefits may include increased organ utilization, reduced staff overtime, and fewer high Model for End-Stage Liver Disease (MELD) transplants. In the review of the organ rejection data, moderate/severe biopsy-proven organ rejection was less common in HOPE than SCS (32% v 67%, p=.033). Ten patients developed steroid resistant organ rejection: one in the HOPE cohort and nine in the SCS group (4% v 43%, p=.003). Researchers concluded that while the prevalence of organ rejection was similar in HOPE and SCS, HOPE was associated with significantly less severe organ rejection and a significantly lower risk of steroid resistant organ rejection. These results highlight the immunomodulatory benefits of HOPE and warrant further research. About Bridge to Life™ LtdBridge to Life™ Ltd is a market leader in organ preservation solutions, offering premier products such as Belzer UW®, EasiSlush® and the VitaSmart™1 Hypothermic Oxygenated Perfusion System. With a strong focus on product quality, innovation and accessibility, the company serves and partners with leading Transplant Centers and Organ Procurement Organizations globally. 1VitaSmart™ is CE Marked and available for sale in several markets outside of the United States. VitaSmart™ is pending FDA approval in the United States. View original content to download multimedia: SOURCE Bridge to Life, Ltd. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
09-07-2025
- Yahoo
Mattel launches Barbie with Type 1 diabetes and a glucose monitor
Barbie is expanding its repertoire with the launch of a doll that has Type 1 diabetes and is outfitted with medical devices, such as a wearable insulin pump, commonly used by people with the condition. Mattel announced the newest member of its Barbie Fashionistas line on Tuesday, saying that it not only lets children see themselves in the doll, but also encourages play "that extends beyond a child's own lived experience." The doll has a continuous glucose monitor attached to her arm and an insulin pump attached to her waist. Krista Berger, senior vice president for Barbie and global head of dolls, said in a news release that the doll "marks an important step in our commitment to inclusivity." "Barbie helps shape children's early perceptions of the world, and by reflecting medical conditions like T1D, we ensure more kids can see themselves in the stories they imagine and the dolls they love," Berger said. The Mayo Clinic defines Type 1 diabetes as a chronic condition that results when a person's pancreas creates little to no insulin, the hormone that helps glucose get into cells, where it's broken down. A glucose monitor allows someone with the condition to keep track of their sugar levels and inject insulin to help their body process glucose. An insulin pump is a wearable device that allows for an easy supply of insulin into the body. More than 18,000 young people under the age of 20 were diagnosed with Type 1 diabetes in the U.S. last year, according to the Centers for Disease Control and Prevention. The agency reported that there's been about a 2% increase per year in diagnosed cases between 2002 and 2018. Barbie partnered with the nonprofit organization Breakthrough T1D in the development of its new doll and to ensure an accurate reflection of the devices, the release said. Breakthrough T1D CEO Aaron J. Kowalski said he was "thrilled" when the company proposed a collaboration. "I have lived with T1D since I was 13, and my brother since he was 3, so this partnership is deeply personal – it means the world to be part of bringing greater visibility to a condition that affects so many families," Kowalski said. A link to buy the doll on Mattel's website appears to already have reviews from parents who were sent the doll, as the website notes the reviews are "incentivized." One parent wrote that they gave the doll to their 7-year-old daughter and it opened up a conversation about diabetes. Another parent called it a "great addition" to the Barbie brand. "We have a close family friend who is T1D, so this was an excellent opportunity to explain what each item was and what it does to help keep people safe and healthy," the review said. This article was originally published on
Business Upturn
09-07-2025
- Business Upturn
Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group Add RadNet's AI-Powered Enhanced Breast Cancer Detection (EBCD) Program to its Membership Benefits in Southern California
By GlobeNewswire Published on July 9, 2025, 15:00 IST Program will increase access to cutting-edge AI-powered breast cancer detection and is designed to boost compliance with annual cancer-screening guidelines Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group are affiliates of one of Southern California's largest health networks, which manages nearly 600,000 members from newborns to Medicare recipients Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group contract with most major health insurance carriers, expanding access to quality care to communities across Southern California Program is indicative of EBCD reimbursement traction RadNet is getting with commercial payors LOS ANGELES, July 09, 2025 (GLOBE NEWSWIRE) — RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announced that Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group, affiliates of Heritage Provider Network (HPN), one of the largest physician-owned medical groups in Southern California, have agreed to reimburse RadNet for its EBCD program — which will now be included as a benefit in their members' health plans. These medical groups predominantly located in Los Angeles, Ventura, Orange, San Bernardino, Riverside and San Diego counties, will now provide the AI-powered breast cancer detection services to all of their mammogram-eligible patients. Additionally, RadNet will launch an ongoing patient-outreach program to increase compliance within these medical groups with annual screening guidelines, by proactively contacting eligible patients to encourage and remind them to make their mammography appointments. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, 'RadNet and the Regal, Lakeside and ADOC medical groups share a commitment to early detection of breast cancer and population health screening. One in eight women will develop breast cancer in her lifetime, making it critical to detect the disease early, when treatment options are most optimal. The AI-powered EBCD program is able to detect breast cancer that otherwise would be found much later, thereby improving patient outcomes by reducing the amount of treatment and/or life impact through early detection.' 'We are excited that Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group are now offering this program to all of their eligible female patients. We recognize their commitment to provide innovative solutions to their patients, and expect that they will pave the way for other significant payors to include EBCD in their benefit plans,' concluded Dr. Berger. Will Jukes, Senior Vice President of Regional Operations at Regal Medical Group, added, 'We continually seek ways to bring leading-edge solutions to patient care. EBCD will increase early cancer detection in addition to traditional radiologist screening, eliminating multiple radiology visits and positively impacting patient outcomes. The collaboration with RadNet will also focus on increasing annual compliance with screening mammography guidelines. Bringing this unique breast cancer screening program to our members is illustrative of our commitment to providing new and leading-edge medicine.' For media inquiries or further information, please contact: RadNet, Inc. Mark Stolper, (310) 445-2800 Executive Vice President and Chief Financial Officer About Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Group Regal Medical Group, Lakeside Community Healthcare and ADOC Medical Groups are affiliates of Heritage Provider Network (HPN), which serves as a trusted healthcare network to nearly 600,000 Southern California members. As one of the largest doctor-owned medical groups in Southern California, HPN and its affiliates are dedicated to providing quality, affordable healthcare. For more information, please visit or About RadNet, Inc. RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
